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In brief
ALS-associated KIF5A mutations alter
the C terminus, the effect of which had yet
to be elucidated. Here, Baron et al.
discover that these mutations impair
KIF5A autoinhibition resulting in a
hyperactive kinesin that displays altered
protein function and aberrant cellular
interactions. These observations shed
light on the mechanisms contributing to
ALS.
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SUMMARY

Understanding the pathogenic mechanisms of disease mutations is critical to advancing treatments. ALS-associated mutations in the gene encoding the microtubule motor KIF5A result in skipping of exon 27 (KIF5ADExon27)
and the encoding of a protein with a novel 39 amino acid residue C-terminal sequence. Here, we report that
expression of ALS-linked mutant KIF5A results in dysregulated motor activity, cellular mislocalization, altered
axonal transport, and decreased neuronal survival. Single-molecule analysis revealed that the altered C terminus of mutant KIF5A results in a constitutively active state. Furthermore, mutant KIF5A possesses altered protein and RNA interactions and its expression results in altered gene expression/splicing. Taken together, our
data support the hypothesis that causative ALS mutations result in a toxic gain of function in the intracellular
motor KIF5A that disrupts intracellular trafficking and neuronal homeostasis.

INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive loss of brain and spinal
cord motor neurons (MNs). As the disease progresses, patients
experience impairment in mobility, speech, and respiration, ultimately leading to death, typically 2–5 years after initial symptom
onset. Although ALS is classified as a rare neurological disorder,
it is the most common motor neuron disease in its class, accounting for about 70% of all the cases in the United States.
Approximately 5,000 people are diagnosed with ALS each year
and approximately 5 per 100,000 die annually in the United
States (Hirtz et al., 2007; Mehta et al., 2018).
Over the past decade, tremendous advances have been made
in defining the genetic factors contributing to ALS. To date, causative mutations for familial ALS have been identified in over 30
genes. Most importantly, the function and classification of these

mutant genes have established the primary pathways contributing to ALS pathogenesis. Cytoskeletal disturbances and
axonal transport deficits are among these primary pathways
(Chevalier-Larsen and Holzbaur, 2006; Eira et al., 2016; Guo
et al., 2020; McMurray, 2000). Furthermore, cytoskeletal/axonal
transport defects extend to several other neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease
(PD), and Huntington’s disease (HD). Supporting the contribution
of these defects to neurodegeneration, we have previously reported mutations within the kinesin family member 5A (KIF5A)
gene as a cause of familial ALS (Nicolas et al., 2018).
Kinesins are a superfamily of microtubule (MT) motor proteins
essential for many cellular functions, including intracellular trafficking and cell division (Hirokawa and Tanaka, 2015).
Kinesin-1 (also known as KIF5) is required for neuronal development and function (Aiken and Holzbaur, 2021). The kinesin-1
core is a dimer of heavy chains (KHCs), each with an N-terminal
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Figure 1. ALS-associated KIF5A mutations are clustered to exon 27 resulting in a common toxic C terminus mutation
(A) KIF5A domain structure. The kinesin light chain domain, the hinge domain, and the regulatory IAK domain are indicated. Arrows in the expanded intron/exon
diagram indicate the ALS-related mutations. A mutation denoted with 14, is positioned 14 bp upstream of exon 27, but still creates the same mutant C terminus.
Image created with Biorender.com.
(B) ALS-associated mutations in KIF5A all lead to a common C-terminal tail as indicated in red. Positively and negatively charged amino acids are underlined and
bolded, respectively.
(C) Electrostatic surface charge distribution images show that the novel mutant C-terminal tail reverses the protein charge density making the mutant tail highly
positively charged.
(D) Expression of the KIF5ADExon27 mutant, but not KIF5ADC-term, in primary mouse cortical neurons leads to increased risk of death compared with KIF5AWT-expressing cells. A representative graph of three biological experiments is shown; n = 597 cells for KIF5AWT, n = 212 cells for KIF5ADExon27, and n = 475 cells for
KIF5ADC-term in the experiment shown. p = 1.4 3 107 by Cox hazard analysis.

motor domain, a hinged coiled-coil stalk, and a globular C-terminal tail domain. The motor domain binds MTs in an ATP-dependent manner, and the coiled-coil domain mediates heavy chain
dimerization and conformational changes within the dimer. The
C-terminal domain serves several functions: (1) cargo binding,
(2) autoinhibition, and (3) MT sliding/bundling (del Castillo et al.,
2015; Yip et al., 2016). This region regulates cargo binding via
binding of kinesin light chains (KLC) and adaptor proteins.
KLCs 1 and 2 may also associate with the motor to further regulate cargo binding and autoinhibition. The alternate ATP-dependent stepping of the motor domains drives cargo movement toward the plus ends of MTs (Skowronek et al., 2007). There are
three kinesin-1 isoforms in mammals: KIF5A, KIF5B, and
KIF5C. KIF5B is ubiquitously expressed in most mammalian
cells, whereas KIF5A and KIF5C are neuron specific (Kanai
et al., 2000; Miki et al., 2001). Kinesin-1 is responsible for the
anterograde axonal transport of diverse cargos in neurons
including mitochondria, lysosomes, RNA granules, and neurofilaments (Hirokawa and Takemura, 2005).
Most cellular kinesin-1 is autoinhibited and unable to bind
either cargo or MTs (Hackney et al., 2009; Kaan et al., 2011;
Yip et al., 2016). Autoinhibition is mediated by a direct intramolecular interaction of the motor domain with a short, charged
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region within the C-terminal region, called the isoleucinealanine-lysine (IAK) motif. In contrast, binding to activators,
such as JIP1 and FEZ1 (Blasius et al., 2007), promotes dimer unfolding and relieves autoinhibition, allowing interaction with
cargo and the MT track.
RESULTS
The C-terminal sequence of mutant KIF5A confers a
toxic gain of function
We previously reported that ALS-associated mutations alter the
KIF5A tail domain (Nicolas et al., 2018). Point mutations located
within the splice acceptor and splice donor region of exon 27
lead to the skipping of this exon (Figure 1A) resulting in a protein
where the C-terminal 34 amino acids (aa) of wild-type KIF5A (KIF5AWT) are replaced with a novel 39 aa sequence (KIF5ADExon27).
Additional studies have similarly identified exon 27 splice site
mutations within ALS and frontotemporal dementia (FTD) patients (Naruse et al., 2021; Saez-Atienzar et al., 2020). Furthermore, an additional three ALS-related single-base-pair deletions
within exon 26 and 27 also predict transcripts with an identical
mutant C terminus (Figure 1B) (Nicolas et al., 2018). Given the
number of charged residues in the C-terminal tail, we examined
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Figure 2. Mutant KIF5A associates more readily with microtubules, displays microtubule plus-end accumulation, and has a dominantnegative effect on wild-type KIF5A
(A) SKNAS cells expressing V5-tagged KIF5ADExon27 show increased microtubule (MT) co-localization compared with KIF5AWT as demonstrated by V5-KIF5A
highlighting the MT tracks. Examples of KIF5A (V5; green) and b-tubulin (red) co-localization are indicated by arrowheads. Many cells have KIF5ADExon27-associated MTs with a non-radial pattern (asterisks). Scale bars, 10 mm (wide view), 5 mm (enlargement).
(B) Quantification of the experiment in (A). n = 5 biological replicates are shown with p < 0.0001.
(C, E, and G). Expression of KIF5ADExon27 results in distal/growth cone accumulation of tagged-KIF5A in transfected SKNAS (C), differentiated N2A (E), and PMN
cells (G). Scale bars, 20 mm (C), 25 mm (E), and 10 mm (G).
(D) Quantification of the percentage of transfected SKNAS cells in (C) with distal accumulation. n = 5 biological replicates are shown with p < 0.0001.
(F) HA intensity analysis of the experiment in (E). n = 3 biological replicates are shown with n R 60 cells per sample.
(H) Quantification of the HA signal intensity from the growth cone compared with that of the cell body for the PMNs in (G). n = 3 biological replicates are shown with
p < 0.0001.
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how the mutant sequence might alter the protein’s charge. While
the isoelectric point (pI) of the whole proteins showed only a
modest change (5.65 in KIF5AWT versus 6.12 in KIF5ADExon27),
comparison of the C-terminal sequences revealed a dramatic
difference in charge (4.14 in KIF5AWT versus 12.13 in
KIF5ADExon27; Figure 1C). Based on these observations, we
speculated that the mutant KIF5A protein contributes to pathogenesis through a toxic gain of function instead of
haploinsufficiency.
To investigate the toxic properties of mutant KIF5A, we
compared the survival of primary cortical neurons expressing
either KIF5AWT or KIF5ADExon27 via automated longitudinal livecell imaging (Arrasate and Finkbeiner, 2005; Linsley et al.,
2019), where the individual lifetimes of large numbers of neurons
are measured. Cox proportional hazards analysis is then used to
generate a hazard ratio (HR) representing an estimate of the relative risk of death for each cohort of neurons. This methodology
has been used extensively to study toxic properties of several
proteins associated with ALS and other neurodegenerative diseases (Barmada et al., 2010, 2014, 2015; Bilican et al., 2012;
HD iPSC Consortium, 2012; Skibinski et al., 2014). Expression
of KIF5ADExon27 resulted in an increased HR compared with the
wild-type protein (HR = 1.69, p = 1.4 3 107; Figure 1D). This
supports, in part, the hypothesis that KIF5ADExon27 acts through
a toxic gain of function. This toxicity could be due to either the
addition of the mutant 39 aa C-terminal tail or the loss of the
wild-type 34 aa from the tail. To distinguish these possibilities,
we further evaluated the neuronal survival of a wild-type KIF5A
protein truncated at aa 998 (KIF5ADC-term), where the wild-type
and mutant tail sequences diverge. Our evaluation revealed
that neurons expressing KIF5ADC-term survived similarly to those
expressing KIF5AWT (HR = 1.04; p = 0.67; Figure 1D). These results suggest that the toxic gain-of-function properties of
KIF5ADExon27 are conferred by the mutant C-terminal sequence.
Mutant KIF5A displays altered binding to MTs, distal
accumulation, and a dominant-negative effect over
wild-type KIF5A
Given the C-terminal charge changes and how that might affect
inter- and intra-protein interactions, we sought to investigate
how this mutation might affect KIF5A’s basic function and localization. Usually, most KIF5A within cells is cytosolic, unbound
from cargo, inhibited by a head-tail association (Cai et al.,
2007; Dietrich et al., 2008; Hackney and Stock, 2000). While inhibited, KIF5A displays a decreased affinity for MTs, whereas
activation causes a marked increase in the KIF5A-MT interaction
(Cai et al., 2007; Friedman and Vale, 1999). We evaluated the
ability of the motor to bind MTs by expressing KIF5AWT and
KIF5ADExon27 in SKNAS cells and evaluated co-localization to
MTs through cellular staining. KIF5AWT displayed a diffuse staining pattern with little MT co-localization. In contrast, nearly 60%
of KIF5ADExon27-expressing cells showed a high degree of colocalization (Figures 2A and 2B). These results suggest that the

Article
effect of the ALS-associated mutation is to attenuate autoinhibition of KIF5ADExon27. Furthermore, we observed that the MT
network within KIF5ADexon27 cells specifically often displayed a
non-radial pattern with numerous loops (Figure 2A, asterisks).
This pattern resembles the MT reorganization seen in cells
exposed to kinesore, an inducer of kinesin-1 activation (Randall
et al., 2017). Finally, we observed distal accumulation of
KIF5ADExon27 in a substantial percentage of cells relative to
KIF5AWT-expressing cells (50% versus 5%) (Figures 2C and
2D), a phenotype observed in vitro with activated forms of
KIF5A (Guardia et al., 2016; Yang et al., 2016). This result
was validated in both differentiated Neuro-2A (N2A) cells and primary mouse motor neurons (PMNs), where expression of
KIF5ADExon27 resulted in a 2-fold increase in distally accumulated protein (Figures 2E–2H). As with the survival assays, the results of KIF5ADC-term expression paralleled KIF5AWT supporting
that mislocalization was dependent on the mutant C terminus
specifically (Figures 2E and 2F).
Kinesin-1 is formed by the dimerization of two heavy chains.
We find that KIF5ADExon27 can homodimerize and heterodimerize
with KIF5AWT (Figures S1A and S1B). Based on this, we asked
whether KIF5ADExon27 can have a dominant-negative effect on
KIF5AWT resulting in mislocalization of both proteins. We
compared the localization of GFP-KIF5AWT in differentiated
N2A cells co-expressing either HA-tagged-KIF5ADExon27 or -KIF5AWT. As shown in Figures 2I and 2J, GFP-KIF5AWT displayed
increased accumulation within distal neurites when co-expressed with HA-KIF5ADExon27 but not when expressed with
HA-KIF5AWT. These results support the hypothesis that
KIF5ADExon27can act in a dominant-negative fashion over
KIF5AWT.
Mutant KIF5A displays defective autoinhibition
KIF5A is autoregulated through the direct intramolecular interaction of the C-terminal IAK motif with the N-terminal motor
domain. In humans, the IAK domain consists of the amino acids
QIAKPIR located at residues 917–923. This sequence is located
upstream of the aberrant ALS-associated mutant tail, which diverges from the wild-type protein at aa 998. Altering this intramolecular interaction, through mutation or deletion of the IAK motif,
for instance, results in a constitutively active kinesin (Cai et al.,
2007). This, in turn, results in increased MT binding (Hackney
and Stock, 2000), altered MT dynamics (Randall et al., 2017),
and accumulation in distal neurites (Seiler et al., 2000). Given
the similarities between these observations and the
KIF5ADExon27 phenotypes, along with the proximity of the mutant
C-terminal tail to the IAK domain, we hypothesize that
KIF5ADExon27 forms a constitutively active kinesin lacking
autoinhibition.
To test this hypothesis, we utilized an in vitro assay to evaluate
the MT-based motility of wild-type and mutant KIF5A (Fenton
et al., 2021). The transport of KIF5A along dynamic MTs was
examined at single-molecule resolution using total internal

(I) Representative images of differentiated N2A cells transfected with GFP-KIF5AWT and either HA-tagged KIF5AWT or KIF5ADExon27. Scale bar, 25 mm. Confirmation of this protein binding is shown in Figure S1B.
(J) Quantification of the GFP intensity along the length of the cells in (I) when different forms of HA-tagged KIF5A are present. n = 3 biological replicates with n R 51
cells analyzed per sample. Data in (B), (D), and (H) are represented as mean ± SD. Data in (F) and (J) are represented as mean ± 95% CI.
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Figure 3. Mutant KIF5A displays qualities of a hyperactive kinesin in axonal transport
(A) Schematic representation of the single-molecule labeling method used to track KIF5A axonal movement.
(B) Representative kymograms showing the effect of KIF5ADCTerm, KIF5ADExon27, and KIF5AK560 mutations on motility compared with KIF5AWT. Scale bars, 5 mm
(distance) and 5 s (time).
(C) Quantification of the ratio of processive runs to total binding events for KIF5A. n = 3–4 biological replicates with p = 0.0022 for K560 versus wild-type, p =
0.0021 for DExon27 versus wild-type and non-significant for DC-term versus wild-type as determined by the Brown-Forsythe ANOVA with Dunnett’s multiple
comparison test.
(D and E) Inverse cumulative distribution functions (CDF) of run length and histogram distributions of velocity for KIF5A transport to the MT plus end (n = 652
events for wild-type, 667 events for DC-term, 1,074 events for DExon27, and 660 events for K560 samples). The curves in CDF graph (D) represent single
exponential decay fits. The values in (C and E) are mean ± SD.
(F) Representative kymograms showing the effect of the KIF5ADExon27 on mitochondrial transport. Scale bar, 30 mm (distance) and 30 s (time).
(G–I) Quantification of mitochondrial transport characteristics. The total number of moving mitochondria (G) are reported as well as anterograde mitochondrial
velocity (H), and retrograde velocity (I). For each experiment n = 3 biological replicates p = 0.017 in (G), 0.032 in (H), and is non-significant (ns) in (I). The data
represented in (G–I) are mean ± SEM.

reflection fluorescence (TIRF) microscopy (Figure 3A). For this
analysis, KIF5ADExon27, KIF5AWT, KIF5ADC-term, and a truncated,
constitutively active construct corresponding to the first 560 aa
residues of KIF5A (KIF5AK560) were compared. All KIF5A
constructs landed on MTs and exhibited processive transport toward the MT plus end (Figure 3B). However, KIF5ADExon27 displayed more frequent motile events (77% versus 31% of binding
events) and longer run lengths (4.6 versus 3.6 mm on average)
than KIF5AWT. The motile properties of KIF5ADExon27 were comparable with those observed for the constitutively active
construct KIF5AK560 (Figures 3C and 3D). In contrast, the
KIF5ADC-term displayed a frequency of motile events and run
lengths comparable with KIF5AWT, supporting that the mutant
C terminus is necessary to disrupt autoinhibition. Of note, the velocity of moving KIF5A molecules did not differ among any of the

expression constructs (Figure 3E), indicating that the activity of
the motor domain remains unaltered despite the loss in autoinhibition seen with KIF5ADExon27. In summary, the properties of
KIF5ADExon27 are consistent with an inability to autoinhibit, resulting in a constitutively active motor.
Mutant KIF5A expression results in increased
movement and velocity of mitochondria
To test how the loss of KIF5A autoinhibition affects neuronal
cargo transport, we examined the effects of wild-type and
mutant KIF5A on mitochondrial transport in PMNs via live-cell
imaging. Mitochondrial axonal transport is a regulated process
that is essential to maintain neuronal integrity. Anterograde
transport of mitochondria is primarily driven by Kinesin-1 (Hollenbeck and Saxton, 2005; van Spronsen et al., 2013).
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Consistently, mitochondrial transport defects have been associated with neurodegenerative diseases, including AD, PD, and
ALS (Guo et al., 2020; McLelland et al., 2014; Millecamps and Julien, 2013; Smith et al., 2019; Wang et al., 2019). Expression of
KIF5ADExon27 resulted in a higher percentage of moving mitochondria with an increased anterograde, but not retrograde, velocity compared with PMNs expressing KIF5AWT (Figures 3F–3I).
Of note, velocities measured in the TIRF assay (Figure 3E) corresponded to processive runs only, excluding pauses, while mitochondrial transport was measured as the average velocity over
the course of the experiment and thus is affected by changes
in either the frequency or durations of pauses. Thus, the increase
in average anterograde velocity of mitochondria may reflect
either an increase in instantaneous velocity or a decreased frequency or duration of pauses during transport. Together, these
data indicate that expression of KIF5ADExon27 alters axonal
transport.
Mutant KIF5A displays altered interactions with proteins
and RNA
KIF5A also functions to transport proteins and RNA. The C-terminal region of KIF5A contributes to the binding of cargo either
directly or through adapters (Cross and Dodding, 2019). With
the aforementioned structural changes present in mutant
KIF5A, we hypothesized that the protein might also exhibit alterations in protein and RNA binding properties. To identify differentially interacting proteins, we transfected SKNAS cells with V5tagged KIF5AWT and KIF5ADExon27 and immunoprecipitated the
tagged proteins (Figure 4A; Table S1). We identified 78 and 21
proteins displaying increased and decreased binding, respectively, to KIF5ADExon27 relative to KIF5AWT. Among the enriched
KIF5ADExon27 interactions were SQSTM1/p62, MOV10, and
UPF1. SQSTM1/p62 functions in the autophagy pathway and
mutations in this protein cause ALS/FTD and Paget disease (Duran et al., 2011; Falchetti et al., 2004; Hocking et al., 2004; Laurin
et al., 2002). UPF1 is an RNA-dependent helicase required for
nonsense-mediated decay (Singh et al., 2008). MOV10 is an
RNA helicase required for miRNA-mediated cleavage of complementary mRNAs by RISC and a mediator of mRNA decay via
interaction with UPF1 (Meister et al., 2005; Nawaz et al., 2021).
While the interaction of KIF5A with these proteins was confirmed
by co-immunoprecipitation/western blotting (Figure 4B), it is
interesting to note that all three of these proteins have been
found in complex previously (Fritzsche et al., 2013; Li et al.,
2015; Soria-Valles et al., 2016). Pathway analysis of the enriched
KIF5ADExon27 interactors (Figures 4C and S2A) revealed several
categories associated with RNA processing, a well-established
process associated with ALS pathogenesis (Butti and Patten,
2018). Similarly, pathway analysis of proteins with reduced
KIF5ADExon27 interactions included ALS-associated categories
of protein stabilization and cellular stress response (Parakh
and Atkin, 2016), suggesting a downstream consequence of
altered binding that leads to disruption of cellular homeostasis.
We next sought to identify differentially bound RNAs using
RIP-seq (Figures 4D and 4E; Table S1). Here, we identified
1,184 and 303 transcripts that displayed enriched and
decreased binding, respectively, to KIF5ADExon27 compared
with KIF5AWT. Pathway analysis again revealed several cate-
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gories related to ALS pathogenesis (Figures 4F and S2B).
KIF5ADExon27-enriched pathways included nerve growth factor
(NGF)-stimulated transcription, which is related to neurite
outgrowth (Liu et al., 2007). Pathways that were underrepresented in KIF5A DExon27 samples included interactions between
L1 and Ankyrins, synapse assembly, and potassium channels.
Hyperexcitability is a hallmark of ALS primarily resulting from
the dysfunction of ion channels (LoRusso et al., 2019). Together,
our results demonstrate that KIF5A mutations can result in
altered protein and RNA interactions associated with ALSrelated pathways.
Mutant KIF5A expression contributes to altered gene
expression and splicing
To circumvent overexpression effects, we created isogenic iPSC
CRISPR lines with a p.Arg1007Lys (c.3020G > A) mutation
(Figures 1A, S3A, and S3B). This mutation was chosen because
it alters an essential splice site sequence and was observed in
two distinct familial ALS cases (Nicolas et al., 2018). The wildtype parental line (Iso Control) and the heterozygous mutant
line (KIF5AR1007K) were differentiated into motor neurons (iMNs)
and subject to RNA-seq. Evaluation of differentiation markers
(Islet/Tuj1) revealed a >85% differentiation efficiency of iPSC to
mature iMNs, which are ChAT and MAP2 positive by DIV15
(Figures 5A–5C). The mutant iMNs faithfully recapitulated the
skipped exon 27 phenotype seen in patients (not shown) and appeared to have a similar level of total KIF5A between the two lines
(Figures S3C and S3D). Interestingly, the level of wild-type protein in the mutant line was 65% that of the isogenic control
(Figures S3E and S3F), suggesting there is 23 more wildtype than mutant protein present in this line.
While altered interactions, MT transport, and localization of
KIF5ADExon27 may be a direct result of constitutive activation,
there are several secondary effects that could occur as well.
As KIF5ADExon27 had been found to have altered interactions
with RNA metabolism-related proteins, we investigated the effects of KIF5ADExon27 on global gene expression. RNA-seq analysis of the iMNs revealed 57 genes displaying altered expression
(Figures 5D and 5E; Table S2). We evaluated six of these genes
by qPCR whose functions were related to enriched pathways
seen in our protein and RNA studies, including NMJ function,
mRNA processing, and neurite outgrowth. All tested genes recapitulated the results observed by RNA-seq (Figure 5E). Pathway
analysis of the altered genes (Figure 5F) suggests that, similar to
our studies in SKNAS cells, expression of ALS-related mutant
KIF5A disrupts RNA metabolism within the cell.
Because so many altered protein interactors are related to
mRNA splicing (Figure 4C), we extended our analysis to investigate whether splicing was altered between the isogenic iMNs.
Differential splicing events were identified with the multivariate
analysis of transcript splicing method (Shen et al., 2014). Using
this tool, we identified 1,919 transcripts with altered splicing
compared with the isogenic control iMNs (Figure 6A; Table S3).
Of these, 1,000 exons and 919 exons showed decreased and
increased skipping, respectively, in KIF5AR1007K lines. Pathway
analysis of each of these groups (Figures 6B, S4A, and S4B) suggests that this group of altered genes, as a whole, represents
cytoskeletal and transport defects in the cell, both of which are
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Figure 4. KIF5A binding partners are altered in cells expressing mutant KIF5A
(A) Mass spectrometry analysis of V5-tagged KIF5AWT and KIF5ADExon27 bound proteins in SKNAS cells. Venn diagram indicates the number of protein binding
partners altered in KIF5ADExon27 mutant immunoprecipitations. Yellow region: proteins that are unique to, or have R43 increase in the amount bound to,
KIF5ADExon27. Red region: proteins that are absent from, or have R43 decrease in the amount bound to, KIF5ADExon27. Orange region: proteins that show no
binding preference to either form of KIF5A.
(B) Validation of several Myc-tagged mass spectrometry hits from (A) by western blotting. Capillary western blots of MOV10 (upper panel) and UPF-1 (middle
panel) show the strong interaction of V5-KIF5ADExon27, but not KIF5AWT. Exposure settings for the capillary western blots were adjusted individually for each
band of interest as needed for each sample set (samples of the same type; ex:. all of the input samples). A traditional western blot of p62 (lower panel) also shows
a unique interaction with V5-KIF5ADExon27. Asterisk: the antibody heavy chain pulled down in the IP. The blot for MOV10, UPF1, and p62 is representative of n = 4,
n = 1, and n = 4 biological replicates, respectively.
(C) Pathway analysis on the proteins enriched (upper) and diminished (lower) in the KIF5ADExon27 mutant mass spectrometry sample.
(D) Analysis of RNAs associated with immunoprecipitated V5-tagged KIF5AWT and KIF5ADExon27 mutant containing complexes. The Venn diagram indicates how
many RNAs had altered interactions with KIF5ADExon27 mutant samples as described in (A).
(E) A volcano plot of RNA immunoprecipitation results sowing significantly altered RNA interactors in red. Data are based on n = 2 biological replicates.
(F) Pathway analysis on the RNAs enriched (left) and diminished (right) in the KIF5ADExon27 mutant sample. See expanded pathway analyses in Figure S2.
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Figure 5. Isogenic iPSCs expressing mutant KIF5A display altered gene expression
(A) Patient-derived Arg1007Lys mutant KIF5A iPSC line and isogenic control differentiated into motor neurons (iMNs) display the MN specific marker, Islet1/2 (red),
and Tuj1 (white) at DIV15. Scale bar, 50 mm.
(B) The differentiation efficiency of KIF5A iMNs at DIV15. Data are representative of n = 3 biological replicates where n = 531 control cells and n = 624 KIF5AR1007K
cells were counted over all experiments.
(C) Staining for maturity markers in DIV15 control iMNs differentiated by this method. At least 100 cells were observed in each of n = 2 biological replicates. Scale
bar, 50 mm.
(D) A volcano plot of RNA-seq analysis of the KIF5AR1007K line and isogenic control showing several genes that are differentially expressed in the mutant. n = 4
biological replicates.
(E) Validation of several of the differentially expressed genes in (D) via qPCR. n = 3 biological replicates, each experiment run in triplicate with p < 0.0001 by twoway ANOVA.
(F) Pathway analysis of differentially expressed genes in (D). Enriched GO terms recapitulate themes of mRNA processing from previous experiments. Data in
(B) and (E) are represented as mean ± SD.

hallmarks of neurodegenerative disease (Chevalier-Larsen and
Holzbaur, 2006; Eira et al., 2016; Guo et al., 2020; McMurray,
2000). To determine which RNA binding proteins (RBPs) could
contribute to the splicing changes, we utilized rMAPS2 (Hwang
et al., 2020), which evaluates enrichment of binding sites for
over 100 RBPs in a position-dependent manner in differentially
spliced genes. This analysis revealed an enrichment of the binding motif for RBM24 (Figure 6C), a multifunctional RNA binding
protein involved with many aspects of mRNA processing and
whose function is essential for cell fate decision and differentiation (Jin et al., 2010; Lin et al., 2018; Xu et al., 2014; Zhang et al.,
2018). We speculate that the decrease in RBM24-mediated
alternative splicing may be due to disruption of RBM24 nuclear:cytoplasmic localization in mutant KIF5A-expressing cells. This
could be directly due to the expression of the mutant protein
as we identified RBM24 RNA as a unique interactor of
KIF5ADExon27 in SKNAS (Table S1), and the redistribution of
KIF5ADExon27 with this RNA bound may result in altered localized
translation of RBM24. Alternatively, sequestration of other
altered protein/RNA binding partners may result in downstream
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deficits in global nucleocytoplasmic transport (NCT) for which
RBM24 is a symptom. This hypothesis was evaluated by staining
RBM24 in SKNAS cells expressing either KIF5AWT or
KIF5ADExon27. Here, we observed that RBM24 has a greater
cytoplasmic localization in KIF5ADExon27-expressing cells supporting our position (Figures 6D and 6E). This result was further
validated in the KIF5AR1007K iMNs (Figures 6F and 6G).
This result could indicate a global NCT defect, so we extended
our investigation to examine the RAN gradient in KIF5A isogenic
iMNs. RAN (ras-related nuclear protein) is a GTP binding protein
essential for transporting macromolecules through the nuclear
pore complex (Matsuura, 2016; Steggerda and Paschal, 2002).
The presence of RAN in the nucleus and cytoplasm of cells establishes a gradient by which the directionality of normal NCT
function is determined (Görlich and Mattaj, 1996; Hutten and
Dormann, 2020). Typically RAN is at a higher density in the
nucleus, but compromised NCT can cause higher protein elevations in the cytoplasm (Görlich and Mattaj, 1996; Hutten and Dormann, 2020; Kodiha et al., 2004). We found that KIF5AR1007K
iMNs had more cytoplasmic RAN than the isogenic control
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Figure 6. Nuclear cytoplasmic transport is disrupted in mutant KIF5A-expressing cells
(A) Volcano plot of splicing analysis results from RNA-seq experiments showing significantly altered genes in KIF5ADExon27 iMNs. Red dots indicate values with
p < 1010. Data are representative of n = 4 biological replicates.

(legend continued on next page)
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(Figures 6H and 6I), demonstrating that mutant KIF5A perturbs
NCT. This is not surprising as dysregulation of NCT has been
implicated in several neurodegenerative diseases, including
ALS, FTD, AD, and HD (Ding and Sepehrimanesh, 2021; Hutten
and Dormann, 2020).
DISCUSSION
Neurodegenerative diseases represent a complex set of disorders in which there is dire need for improved therapeutics.
Increased comprehension of the mechanisms underlying these
diseases is an essential step toward the development of effective therapies. To date, causative mutations in over 30 genes
for ALS have been identified. Among these, we previously identified several mutations within KIF5A in familial ALS that result in
a common aberrant C-terminal tail. How these ALS mutations in
KIF5A lead to MN death and the molecular mechanisms that
cause pathology in cells are not understood. We examined the
pathogenic effects of ALS mutant KIF5A, showing that mutant
KIF5A confers a toxic gain of function via its altered C-terminal
tail (Figure 7). Specifically, this mutation causes KIF5A hyperactivity, likely due the negative charge of the KIF5ADExon27 C-terminal tail. It is not understood how a charge reversal could impact
the overall structure of mutant KIF5A; however, it is known that
an adjacent region with a positive charge is essential in maintaining the stable tail-head association necessary for KIF5A inactivation (Wong and Rice, 2010).
Defects in axonal transport have long been established as a
hallmark feature in neurodegenerative diseases (ChevalierLarsen and Holzbaur, 2006; Guo et al., 2020). Of particular interest, C9ORF72 repeat-expansion results in arginine-rich di-peptide repeats that directly impede dynein and kinesin-1 movement
through physical interaction with the axonal transport machinery
(Fumagalli et al., 2021). The data supporting the distal accumulation of KIF5A and increased movement of cargo, raises the
possibility that mutant KIF5A may lack re-cycling properties
and that mitochondria and other cargo accumulate distally.
Since mitochondria are an important cellular organelle for cell
health and function, their abnormal neuronal location could
possibly lead to cellular toxicity and death.
Mutant KIF5A displays aberrant binding to several proteins.
Pathway analysis revealed that altered binding interactions influence RNA processing-related pathways. These pathways are

Article
well established as contributing to ALS pathogenesis. Among
the proteins displaying increased binding to mutant KIF5A are
UPF1 and MOV10. UPF-1 and MOV10 are RNA helicases that
are important for non-sense-mediated decay. Interestingly, Barmada et al. (2015) showed that expression of either UPF-1 or
MOV10 resulted in reduced cell death in mutant TDP-43-expressing primary neurons. This suggests that UPF-1 and
MOV10 might be critical proteins to maintain overall cell health
and survival. Mutant KIF5A also displayed increased binding to
p62/SQSTM1. Mutations in p62/SQSTM1 are a cause of familial
ALS (Fecto et al., 2011). Knockout of p62/SQSTM1 in mice results in neurodegeneration (Ramesh Babu et al., 2008) and
reduced levels of p62 in a zebrafish model cause ALS-like phenotypes (Lattante et al., 2015). These results suggest that the
binding to mutant KIF5A inactivates these proteins from performing their normal function. However, further studies are
needed to determine the mechanisms by which KIF5A binding
leads to their inactivation.
Mutant KIF5A also displays altered interactions with RNA species. Pathways associated with RNAs displaying increased binding include NGF-transcription, supporting neuronal survival, MT
assembly, and homeostatic processes. We further reported that
EGR1 and FosB mRNA display a high level of enrichment of
mutant KIF5A binding. EGR1 is highly expressed in the brain,
regulates pathways involved in synaptic plasticity and maintains
synaptic homeostasis at the neuromuscular junction (MacDonald et al., 2017). Interestingly, EGR1 knockout mice show
decreased limb muscle strength affecting motor functions
(Jones et al., 2001). FosB RNA has previously been shown to
interact with UPF1 and this binding is enhanced in epileptic samples (Mooney et al., 2017). Intriguingly, FosB displays increased
binding to mutant FUS. Furthermore, increased axonal branching results from mutant FUS can be rescued by reducing the
expression of FosB RNA (Akiyama et al., 2019).
Here, we have shown that ALS-associated mutations result in
a loss of autoinhibition leading to disease pathogenesis.
Remarkably, there are several examples of disease-causing
pathogenic mutations within a kinesin gene that result in hyperactivation. Heterozygous KIF21A mutations, which heavily occur
in its third coiled-coil domain with a few in the motor domain,
result in the ocular motility disorder congenital fibrosis of the extraocular muscles type 1 (Yamada et al., 2003). Interestingly, autoregulation of KIF21A is accomplished through interaction of

(B) Pathway analysis of genes where decreased (top) or increased (bottom) exon skipping is observed. The number of affected exons in each group are listed in
parentheses. See expanded pathway analyses in Figure S4.
(C) Motif mapping identifies enrichment of RBM24 binding sites in alternatively spliced genes (p < 1010).
(D) Micrographs of SKNAS cells transfected with either GFP alone or V5-tagged KIF5AWT or KIF5ADExon27 (green) and stained for RBM24 (red) show that RBM24
localization is altered in KIF5ADExon27-expressing cells. Scale bar, 20 mm. Cells outlined with yellow dashed lines show examples of this phenomena.
(E) Quantification of the RBM24 staining intensity in the nucleus versus the cytoplasm (N:C) in SKNAS transfected cells represented in (D). Graph represents data
from 171 KIF5AWT and 176 KIF5ADExon27 cells collected over n = 4 biological replicates with p < 0.0001.
(F) Max projected micrographs of KIF5AR1007K and isogenic control iMNs stained with RBM24 (green), DAPI (blue), and Tuj1 (white) confirm the N:C ratio dysregulation seen in SKNAS cells. Scale bar, 5 mm.
(G) Quantification of RBM24 localization in cells represented in (F). Graph represents data from 116 isogenic control and 124 KIF5AR1007K iMNs collected over n =
4 biological replicates with p < 0.0001.
(H) Max projected micrographs of KIF5AR1007K and isogenic control iMNs stained with RAN (green), DAPI (blue), and Tuj1 (white) shows expression of KIF5AR1007K
in differentiated iMNs alters RAN localization in these cells Scale bar, 5 mm.
(I) Quantification of RAN localization in cells represented in (H). Graph represents data from 89 isogenic controls and 92 KIF5AR1007K iMNs collected over n = 3
biological replicates with p < 0.0001. Data in (E), (G), and (I) are represented as mean ± SEM.
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Figure 7. Schematic of how expression of ALS-related mutant KIF5A affects cellular homeostasis leading to cellular toxicity
ALS-related KIF5A mutations lead to defective autoinhibition (I). As a result, KIF5A has increased binding to MTs and altered axonal transport (II), MT remodeling
(III), and growth cone accumulation (IV). The protein and RNA binding partners of mutant KIF5A are also changed (V). On a global scale, differences in gene
expression (VI) occur as well as NCT disruptions (VIII) which may affect gene splicing (VII). Ultimately the disruption of cellular homeostasis leads to cellular toxicity
and death. This image was created with BioRender.com.

these domains and the pathogenic mutations within both domains relieve autoinhibition. Mutant KIF21A displays several
characteristics of ALS-associated mutant KIF5A including
increased binding to MTs, axonal growth cone accumulation,
altered MT dynamics, and an increased frequency of movements upon MT binding. Missense mutations in the KIF21B
gene result in neurodevelopmental delays and brain malformations. Pathogenic mutations within a region of the second
coiled-coil domain regulate autoinhibition through the intramolecular binding to the motor domain (van Riel et al., 2017). Mutations in KIF21B relieve autoinhibition enhancing binding to MTs
and motor activity resulting in impaired neuronal migration (Asselin et al., 2020). Numerous mutations in KIF1A are associated
with various neuronal diseases and intellectual disabilities. At
least 10 point mutations in KIF1A lead to hereditary spastic paraplegia and, in general, are thought to inhibit motor activity. Chiba

et al. (2019) demonstrated that a subset of mutations results in
hyperactive KIF1A, resulting in overactive transport of synaptic
vesicle precursors. The kinesin KIF22 contributes to the alignment of the chromosome during mitosis. Heterozygous mutations in KIF22 result in spondyloepimetaphyseal dysplasia with
joint laxity, leptodactylic type (Boyden et al., 2011; Min et al.,
2011; Thompson et al., 2021). Pathogenic mutations in KIF22,
observed in two adjacent amino acids in the motor domain or
a single amino acid within the coiled-coil domain, disrupt chromosome segregation in anaphase. Expression of a constitutively
active KIF22 displays similar properties, suggesting that these
mutations attenuate the autoinhibition of KIF22 (Thompson
et al., 2021). There is also suggestive evidence that mutations
in KIF7 that relieve autoinhibition may contribute to human disease (Blasius et al., 2021; Thompson et al., 2021). Taken
together, mutations that attenuate or abolish the autoinhibition
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may represent a converging mechanism of pathogenesis for kinesin-associated diseases.
Limitations of the study
It should be noted that several of the experiments leading to the
conclusion that ALS-related mutations in KIF5A attenuate autoinhibition and alter protein/RNA binding are based on the overexpression of mutant KIF5A within cell lines. Overexpression
systems do have their shortcomings, although in some cases
they are necessary to recapitulate a disease phenotype within
the general limitations of experiments. Nonetheless, they do
not necessarily reflect the true cellular environment with patients
carrying KIF5A mutations. Here, we have supplemented our
investigation with the development of isogenic iPSC lines
harboring a KIF5A mutations. However, our investigation did
not directly address whether several of the aberrant KIF5A functions observed in our cellular in vitro overexpression system are
recapitulated within the mutant iMN lines. Further studies will be
focused toward accomplishing this goal.
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RRID: AB_2492288

Donkey Anti-Rabbit IgG 594

Jackson Immunoresearch

RRID: AB_2340621

Donkey anti-Mouse 546

Invitrogen

Cat# A10036

Mouse anti-Hemagglutinin (HA) antibody
(12CA5)

Invitrogen

Cat# MA1-12429;
RRID: AB_1074049

Goat anti-Mouse FITC

Jackson Immunoresearch

Cat# 115-095-003;
RRID: AB_2338589

Goat anti-Mouse TRITC

Jackson Immunoresearch

Cat#115-025-003;
RRID: AB_2338478

Rabbit anti-GFP

Proteintech

Cat# 50430-2-AP

Goat anti-Mouse HRP

Jackson Immunoresearch

Cat# 115-035-003;
RRID: AB_10015289

Goat anti-Rabbit HRP

Jackson Immunoresearch

Cat# 111-004-003;
RRID: AB_2337913

Patient Kif5A iPSC

Applied Stem Cell; This paper

N/A

Isogenic Control iPSC

Applied Stem Cell

ASE-9109

FuGENE6 transfection reagent

Promega

Cat# E269A

Tetramethylrhodamine (TMR) Halo ligand

Promega

Cat# G8251

Jena Bioscience

Cat# NU-405

Biological samples

Chemicals, peptides, and recombinant proteins

0

Guanosine-5 -[(a,b)-methyleno]
triphosphate, sodium salt (GMPCPP)

(Continued on next page)
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Porcine brain tubulin

Cytoskeleton

Cat# T240

HiLyte488-labeled tubulin

Cytoskeleton

Cat# TL488M

Purified Rigor Kinesin

Masucci et al. (2021)

N/A

PlusOne Repel-Silane ES

Cytiva

Cat# 17133201

Pluronic F-127

Sigma-Aldrich

Cat# P2443

Methyl cellulose

Sigma-Aldrich

Cat# M0512

Adenosine 5’-triphosphate magnesium salt
(ATP)

Sigma-Aldrich

Cat# A9187

Guanosine 50 -triphosphate sodium salt
hydrate (GTP)

Sigma-Aldrich

Cat# G8877

0.05% Trypsin EDTA

Gibco

Cat# 25300054

Poly-D-Lysine

Sigma-Aldrich

Cat# P7280-5X5MG

Natural Mouse Laminin

Corning

Cat# 354232

Neurobasal Medium, Minus Phenol Red

Gibco

Cat# 12348–017

B27 Supplement

Gibco

Cat# 17504–044

Glutamax

Gibco

Cat# 35050061

Opti-MEM I Reduced Serum Medium, no
phenol red

Gibco

Cat# 11058021

Lipofectamine 2000 Transfection Reagent

Invitrogen

Cat# 11668019

2-Mercaptoethanol, 99% pure

Fisher Scientific

Cat# AC125470100

Dulbecco’s Modified Eagle Medium
(DMEM)

Gibco

Cat# 11965118

Fetal Bovine Serum, Regular

MediaTech

Cat# 35-010-CV

L-glutamine (200 mM)

Gibco

Cat# 25030081

Penicillin/Streptomycin

Gibco

Cat# 15140122

NeuroMag Transfection Reagent

Oz Biosciences

Cat# NM50200

Minimum Essential Media (MEM)

Gibco

Cat# 11095098

BSA (heat shock fraction, protease free)

Sigma-Aldrich

Cat# A3294

Triton X-

Sigma-Aldrich

Cat# T9284

Antigen Retrieval Buffer

Abcam

Cat# 93678

Prolong Gold Antifade Mountant with DAPI

Invitrogen

Cat# P-36931

Hank’s Balanced Salt Solution (HBSS)

Gibco

Cat# 14175095

SUPERaseIn RNase Inhibitor

Invitrogen

Cat# AM2694

TRIzol Reagent

Life Technologies

Cat# 15596026

Denaturing Hypotonic Lysis buffer (DHL)

Singh et al. (2014)

N/A

Alt-R S.p. HiFi Cas9 Nuclease v3

Integrated DNA Technologies

Cat# 1081060

Blasticidin S Hydrochloride Powder

Research Products International

Cat# B12200

Ultrapure DNase/RNase-Free Distilled Water

Invitrogen

Cat# 10977015

SalI Restriction Enzyme

New England Biolabs

Cat# R0138L

NotI Restriction Enzyme

New England Biolabs

Cat# R3198L

Proteinase K

Thermo Scientific

Cat# FEREO0491

Laemmli SDS-Sample Buffer

Boston BioProducts

Cat# BP-111R

‘Soft Elution Buffer’

Antrobus and Borner (2011)

N/A

Dulbecco’s Phosphate Buffered Saline

Corning

Cat# 20-031-CV

Tween 20

Fisher BioReagents

Cat# BP337-500

Dithiothrieitol Solution

Sigma-Aldrich

Cat# 43816

Trypsin-EDTA

Gibco

Cat# 15400054

Odyssey Blocking Buffer

Licor

Cat# 927–40010
(Continued on next page)
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Dulbecco’s Modified Eagle Medium

Sigma-Aldrich

Cat# D7777

Heat-Inactivated Fetal Bovine Serum

Corning

Cat# MT35011CV

All trans Retinoic Acid

Sigma-Aldrich

Cat# R2625

Lipofectamine 3000

Invitrogen

Cat# L3000015

Poly-DL-Lysine

Sigma-Aldrich

Cat# P9011

Formaldehyde

Fisher

Cat# BP531-500

BSA (lyophilized powder)

Sigma-Aldrich

Cat# A9418

Triton X-100

Sigma-Aldrich

Cat# X-100

Mowiol 4–88 Reagent

Calbiochem

Cat# 47-590-4100GM

Sepharose GFP-Binder Beads

Gift from Vladimir Gelfand Lab

N/A

Accutase Cell Detachment Solution

Corning

Cat# MT25058CI

Matrigel hESC-Qualified Matrix

Corning

Cat# 08-774-552

ROCK Inhibitor

Selleck Chemicals

Cat# S1049

Lipofectamine Stem Transfection Reagent

Invitrogen

Cat# STEM00001

Chelex 100 Sodium form

Sigma-Aldrich

Cat# C7901

Stemflex Medium

Gibco

Cat# A3349401

B27 Plus Neuronal Culture System

Gibco

Cat# A3653401

Poly D-L-Ornithine

Sigma

Cat# P3655 (3000–7000 kDa)

Laminin

Invitrogen

Cat# 23017–015

Neurobasal medium

Invitrogen

Cat# 21103–049

Glutamax 200mM

Invitrogen

Cat# 35050–061

B27

Invitrogen

Cat# 17504–044

hsBDNF

PeproTech

Cat# 450–02

rnCNTF

PeproTech

Cat# 450–50

mmGDNF

PeproTech

Cat# 450–44

Horse Serum

Sigma

Cat# H1138-100ML

BSA

Gold Biotechnology

Cat# A-421-50

4–20% Mini-PROTEAN TGXTM Gel, 15
well, 15 mL

Bio-Rad

Cat# 456–1096

Nitrocellulose membrane/filter paper pack,
pkg of 50

Bo-Rad

Cat# 1620213

Protease inhibitor tables

Roche

Cat# 11873580001

NeuroMag paramagnetic beads

Oz Biosciences

Cat# NM50200

Magnetic plate

Oz Biosciences

Cat# MF10000

Pierce BCA Protein Assay Kit

ThermoFisher Scientific

Cat# 23227

AmpliTaq Gold 360 Master Mix

Applied Biosystems

Cat# 4398876

High Capacity cDNA Reverse
Transcription Kit

Applied Biosystems

Cat# 436814

TaqMan Fast Advanced Master Mix

Applied Biosystems

Cat# 4444556

Taqman Gene Expression Assay, SLITRK2

ThermoFisher Scientific

Hs01028461_s1

Critical commercial assays

Taqman Gene Expression Assay, TCEAL2

ThermoFisher Scientific

Hs04194669_sH

Taqman Gene Expression Assay,
PCDHA13

ThermoFisher Scientific

Hs00259032_s1

Taqman Gene Expression Assay, HNRNPM

ThermoFisher Scientific

Hs01115690_m1

Taqman Gene Expression Assay, DNAJA4

ThermoFisher Scientific

Hs00388055_m1

Taqman Gene Expression Assay, ELAVL4

ThermoFisher Scientific

Hs00956610_mH

Taqman Gene Expression Assay, GAPDH

ThermoFisher Scientific

Hs02786624_g1
(Continued on next page)
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NEBuilder HiFi DNA Assembly Cloning Kit

New England Biolabs

Cat# E5520S

HiSpeed Plasmid Midi Kit

Qiagen

Cat# 12662

PureLink HiPure Plasmid Midiprep Kit

Invitrogen

Cat# K210005

Sequence data, analyses, and resources
related to the RIPseq of V5-KIF5AD and
V5-KIF5ADExon27 immunoprecipitation
eluates

This paper

Gene Expression Omnibus GSE196539

Sequence data, analyses, and resources
related to the RNA sequencing of
KIF5AR1007K and isogenic control iMNs

This paper

Gene Expression Omnibus GSE196539

Sequence data, analyses and resources
related to the mass spectrometry analysis
of V5-KIF5AWT and V5-KIF5ADExon27
immunoprecipitation eluates

This paper

ProteomeXchange; PXD031012

Deposited data

Experimental models: Cell lines
COS-7

ATCC

CRL-1651; RRID:CVCL_0224

SKNAS

ATCC

CRL-2137; RRID:CVCL_1700

HEK293FT

Invitrogen

R70007

Neuro2A

ATCC

CCL-131; RRID:CVCL_0470

Charles River Laboratories

Cat# 027

sgRNA targeting CYBL
locus – ATGTTGGAAGGATGAGGAAA

Fernandopulle et al. (2018)

N/A

Primer for HA-KIF5A Forward –
ACTGACGCTAGCCACCATGTACCCA
TACGATGTTCCAGATTACGCTGGTG
GTTCTGGTGGTGGTTCTGGTATGGC
GGAGACCAACAACG

This Paper

N/A

Primer for HA-KIF5A WT Reverse –
AGAATCGGATCCTGTGGGAGAT
TAGCTGGCTG

This Paper

N/A

Primer for HA-KIF5A Del27 Reverse –
AGATACGGATCCCGAAGTTATGG
TACCTTAGAAACTGA

This Paper

N/A

Primer for HA-KIF5A C-Term Reverse –
AGAATCGGATCCTTATCCATTGTCCAT
GTTGGCCTT

This Paper

N/A

Primer for eGFP Forward –
AGTCAGGCTAGCCACCATGGTGA
GCAAGGGAGAGGAG

This Paper

N/A

Primer for eGFP Reverse –
AGATACGGATCCCTTGTACAGCT
CGTCCATGCC

This Paper

N/A

Primer for GFP-KIF5A Forward –
AGTCAGGGATCCGGTGGTTC
TGGTGGTGGTTCTGGTATGG
CGGAGACCAACAACG

This Paper

N/A

Primer for GFP-KIF5A WT Reverse –
AGATACTCTAGATGTGGGAGATT
AGCTGGCTG

This Paper

N/A

Experimental models: Organisms/strains
C57BL/6 female mice (primary neuron
preps)
Oligonucleotides

(Continued on next page)
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DsRed-Mito

Takara Bio

Cat# 632421

pRK5:Myc-KIF5A

Addgene

Clone# 127616

pRK5-Myc-KIF5AWT-Halo

This paper

N/A

pRK5-Myc- KIF5ADExon27-Halo

This paper

N/A

pRK5-Myc-KIF5ADC-term-Halo

This paper

N/A

pRK5-Myc-KIF5A1-560-Halo

This paper

N/A

pcDNA4TO-K560-E236A-24xGCN4_
v1-IRES-Puro

Tanenbaum et al. (2014)

Addgene Clone #60909

Recombinant DNA

pGW1-Kif5AWT

This paper

N/A

pGW1-Kif5ADExon27

This paper

N/A

pGW1-Kif5ADC-term

This paper

N/A

pGW1-tdTomato

This paper

N/A

V5-Kif5ADExon27

This paper

Addgene Clone
#15239

V5-Kif5AWT

This paper

Addgene Clone #15239

GFP-Kif5AWT

This paper

Addgene Clone #15239

HA-Kif5AWT

This paper

Addgene Clone #15239

Kif5ADExon27

This paper

N/A

pCMV-beta-Rat Lic1.FL-HA

Tynan et al. (2000)

N/A

pMyc-MOV10

Addgene

Cat# 10977

RNT1-GFP

Addgene

Cat# 17708

HA-p62

Addgene

Cat# 28027

pCDNA 3.1 (+) HA- KIF5A WT

This Paper

N/A

pCDNA 3.1 (+) HA- KIF5A Del27

This Paper

N/A

pCDNA 3.1 (+) HA- KIF5A C-Term

This Paper

N/A

pCDNA 3.1 (+) GFP-KIF5A WT

This Paper

N/A

pCDNA 3.1 (+) GFP- KIF5A Del27

This Paper

N/A

FastQC

Babraham Institute

http://www.bioinformatics.babraham.ac.
uk/projects/fastqc/

MultiQC

Ewels et al. (2016)

https://github.com/ewels/MultiQC

STAR aligner (2.7.0a)

Dobin et al. (2013)

https://github.com/alexdobin/STAR

HTSeq

Anders et al. (2015)

https://htseq.readthedocs.io/en/master/
overview.html

DESeq2

Love et al. (2014)

https://bioconductor.org/packages/
release/bioc/html/DESeq2.html

rMATS version 4.0.2

Shen et al. (2014)

http://rnaseq-mats.sourceforge.net/

Metascape

Zhou et al. (2019)

https://metascape.org/gp/index.html#/
main/step1

rMAPS2

Hwang et al. (2020)

http://rmaps.cecsresearch.org/

ImageJ

NIH

https://imagej.nih.gov/ij/

MTrackJ

NIH

https://imagescience.org/meijering/
software/mtrackj/

Volocity

PerkinElmer

https://www.perkinelmer.com

Prism 9

GraphPad

https://www.graphpad.com/
scientific-software/prism

Survival Analysis YOLO

This paper

https://drive.google.com/drive/folders/
1V36q_9QjX_0SHbLS_
IN2PPngOSLKYS1_?usp=sharing

Software and algorithms

(Continued on next page)
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Biorender

Biorender

https://www.biorender.com

AutoQuant x3

Media Cybernetics

https://www.mediacy.com/79-products/
autoquant-x3

Proteome Discoverer 2.1.1.21

Thermo Scientific

https://www.thermofisher.com/us/en/
home/industrial/mass-spectrometry/
liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/
multi-omics-data-analysis/
proteome-discoverer-software.html

Mascot Server 2.6.2

Matrix Science Ltd.

http://www.matrixscience.com/

Scaffold 4.10.0

Proteome Software, Inc.

https://www.proteomesoftware.com/
products/scaffold-5

Peptide Prophet

Keller et al. (2002); Nesvizhskii et al. (2003)

http://peptideprophet.sourceforge.net/

PyMOL

The PyMOL Molecular Graphics System,
Version 2.0 Schrödinger, LLC

https://pymol.org/2/

I-TASSER

Yang et al. (2015)

https://zhanggroup.org/I-TASSER/

Cytation 5 Cell Imaging Multi Mode Reader

Agilent (BioTek)

https://www.biotek.com/products/
imaging-microscopy-cell-imaging-multimode-readers/cytation-5-cell-imagingmulti-mode-reader/

BioSpa 8 Automated Incubator

Agilent (BioTek)

https://www.biotek.com/products/
software-robotics-robotics/
biospa-8-automated-incubator/

Nikon Ti Eclipse

Nikon

Ti Eclipse

Leica DMI6000 Widefield Microscope

Leica Microsystems

DMI6000

Anti-V5 Tagged Magnetic Beads

MBL International

Cat#M167-11

CFX 384 Real-Time PCR Detection System

BioRad

https://www.bio-rad.com/en-us/product/
cfx384-touch-real-time-pcr-detectionsystem?ID=LJB22YE8Z

C1000 Touch Thermal Cycler

BioRad

https://www.bio-rad.com/en-us/sku/
1851138-c1000-touch-thermal-cyclerwith-384-well-reaction-module?
ID=1851138

Trans-Blot Turbo Transfer System

BioRad

Cat# 1704150

Other

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to, and will be fulfilled by, the lead contact, Dr. John
Landers (John.Landers@umassmed.edu).
Materials availability
New cell lines and materials made during this study will be made available upon request to the lead contact Dr. John Landers (John.
Landers@umassmed.edu) subject to the completion of a materials transfer agreement.
Data and code availability
d The raw RNA Seq data files have been deposited to Gene Expression Omnibus (GEO) and are publicly available as of the date of
publication. The raw Mass Spec data files are available at ProteomeXchange. Accession numbers for all datasets are listed in
the Key resources table. Microscopy data reported in this paper will be shared by the lead contact upon request.
d All original code and pipelines used for analysis of the time-lapse survival data is available for download as of the date of publication at Google Drive. The resource link is listed in the Key resources table.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Immortalized and primary cell culture
SKNAS human neuroblastoma cells (ATCC) were maintained at 37C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (MediaTech), 2 mM L-glutamine (Gibco) and 1%
(v/v) penicillin and streptomycin solution (Gibco). COS-7 cells (ATCC, CRL-1651) were maintained in DMEM supplemented with 10%
(v/v) FBS and 2 mM glutamax (GIBCO). N2A cells (ATCC) and HEK293FT cells were maintained at 37 C with 5% CO2 in standard
growth media DMEM (Sigma) supplemented with 10% (v/v) FBS (Corning) and 1% (v/v) penicillin and streptomycin solution (Fisher).
All biological replicates were done on cells from the same passage and N2A cells were discarded after passage 30. For differentiation, N2A cells were maintained in differentiation media: DMEM supplemented with 1% FBS, 10 mm all trans Retinoic Acid (Sigma),
and 1% (v/v) penicillin and streptomycin solution (Fisher).
Primary mouse cortical neurons (E14-16) were isolated from C57BL/6 mice and cultured as described previously (Giampetruzzi et al., 2019). Briefly, primary cortical neurons were plated on poly-D-lysine (0.125 mg/mL, Sigma-Aldrich P72805X5MG) and natural mouse laminin (5mg/mL, Corning 354232) coated 384-well plates at 300,000 cells/mL and grown at
37 C and 5% CO2 in Neurobasal medium (Gibco 12348–017) supplemented with 2% B27 (Gibco 17504–044) and 1% Glutamax
(Gibco 35050061). PMNs from C57BL/6 mice were isolated and cultured as described previously (Fallini et al., 2010). Briefly,
PMNs (E12.5) from C57BL/6 mice were plated on poly-D-L-Ornithine (Sigma) coated coverslips that were painted with laminin
(Invitrogen) right before plating. Cells were grown at 37 C and 5% CO2 in MN media (Neurobasal, 0.5 mM Glutamax, 2% horse
serum, 2% B27, 10 ng/mL BDNF, CNTF, and GDNF, 0.04% b-mercaptoethanol) until the day of the experiment. All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at
UMASS Medical School (Protocol #PROTO201900275). Embryos from pregnant adult female mice were used for these
experiments.
IPS cell culture and differentiation
iPSCs were maintained and differentiated into motor neurons using induction protocols described in a methods paper previously
(Fernandopulle et al., 2018) with a few modifications. First the cells were replated after induction at lower densities than described,
approximately 52,000/cm2. Second, the induced cells were replated on a 1:1 mixture of 1X PDL:PLO, the latter being diluted from the
described 10x stock in ultrapure water (Invitrogen). Third, the incubation in IM media + BrdU was extended to 72 h. Finally, the MN
media was made with the Neurobasal Plus system components (Invitrogen) and was refreshed every 2–3 days with ½ volume media
changes until the day of the experiment. The iPSC lines harboring the KIF5AR1007K heterozygous mutation were CRISPR engineered
from the ASE9109 line (Isogenic control) by Applied Stem Cell (Milpitas, California). All iPSC lines used were confirmed to have a
normal karyotype (Quest Diagnostics) prior to making inducible lines.
Creation and characterization of KIF5A NIL iPSC lines
The CYBL1 targeting NIL cassette used to create the inducible cell lines (a gift of Dr. Ward) had been modified from (Fernandopulle et al., 2018) to contain a blasticidin selection marker. To transfect the cassette into IPS cells, the cells were
grown to 80% confluency before dissociating them to single cells with accutase and plating 50,000 cells into a Matrigel
(Corning) coated wells of a 24-well plate (one well for each line made) in Stemflex media (Invitrogen) + 10uM ROCK inhibitor
(RI, Selleck Chemicals). The next day, the media was refreshed and the cells were incubated at 37 C for 1h before transfection. The RNP complex solution was made by mixing the following per well to be transfected: 3 ml of 1 mM sgRNA (Synthego, ATGTTGGAAGGATGAGGAAA) + 3 ml of 1 mM Hifi Cas9 (IDT) + 19 ml of OptiMEM1 (Invitrogen) and incubating at RT
for 5 min. After the incubation, 500 ng of the NIL cassette construct was added to the RNP complex solution and mixed by
pipetting. In a second tube, 25 mL of OptiMEM1 (Invitrogen) + 1 ml Lipofectamine STEM (Invitrogen) was mixed by flicking
the tube. The contents of the latter tube were added to the former tube, mixed by flicking the tube, and incubated at RT for
10 min. During the incubation, the Stemflex + RI media was removed from the wells and replaced with 0.5 mL of
OptiMEM1+ RI. After the incubation, 50 ul of the transfection mix was added to each well to incubate at 37 C for 4 h until
0.5 mL of Stemflex media (Invitrogen) was added. At 1 day post-transfection (dpt) the cells were dissociated to single cells
with accutase and plated in 3 wells of 6 well Matrigel-coated plate in 50% serial dilution series in Stemflex + RI. At 2 dpt,
the Stemflex media (Invitrogen) was replaced with media containing 25ug/mL blasticidin (RPI international) to select for positive transductants. The selection media was refreshed every two days until the remaining cells established colonies. Blasticidin-resistant colonies were scored for the percentage of mApple + transformants present. Colonies that were R90%
mApple+ were selected for expansion and further validation. DNA was collected from IPS cells using a 15% Chelex w/v
(Sigma) in 10 mM Tris, 0.1 mM EDTA, pH 8.0 and heating at 100 C for 20 min. NIL-IPS lines were validated for integration
of the NIL cassette as described previously (Fernandopulle et al., 2018), using AmpliTaq Gold 360 master mix (Thermo
Fisher Scientific) and an annealing temperature of 55 C. Stem cell identity of the NIL lines was confirmed by immunofluorescence staining of the pluripotency markers Oct4 and Sox2 (see below) and normal Karyotype was confirmed thorough
diagnostic testing (Quest Diagnostics).
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METHOD DETAILS
Plasmids used for this study
The KIF5AWT, KIF5ADExon27, and KIF5ADC-term constructs in the N-terminal GFP tagging plasmid, peGFP-C1, were used to make the
other tagged versions of KIF5A. In each case, the GFP tag was removed and the V5 or HA tag was inserted via Gibson assembly. The
pMyc-MOV10 plasmid was acquired from Addgene (#10977). The Myc-tagged UPF1 construct was made in a 2-step Hifi Assembly
process. First, MOV10 was removed from the aforementioned plasmid with SalI/NotI digest. Using the UPF1-GFP construct (Addgene, 17708) the UPF1 gene + 20 bp overhangs homologous to the digested pMyc plasmid were PCR amplified. The UPF1 PCR product was inserted into the pMyc plasmid using the Hifi Assembly kit (New England Biolabs) following the manufacturer’s instructions.
To correct a deletion of a GC-rich region in the N-terminal portion of UPF1 created by the PCR amplification, a second round of Hifi
Assembly was done. The intermediate construct was digested with SalI to remove the mutated N-terminal portion of the gene and a
gblock with the correct sequence was constructed (IDT) and inserted into the digested construct using a Hifi Assembly kit (New England Biolab). Myc-p62 was created by subcloning the p62 gene from a p62-HA construct (Addgene, 28027) into the pMyc plasmid. A
SalI and NotI restriction site were PCR amplified onto the N- and C-terminus, respectively, of the p62 gene and then subcloned into a
SalI/NotI digested pMyc plasmid backbone. All constructs were confirmed through sequencing and prepped with a Maxi prep kit
(Qiagen) following the manufacturer’s instructions.
To generate pCDNA3.1 N-terminal GFP -tagged KIF5A constructs for N2A experiments, eGFP was first cloned by PCR and ligated
into Nhe1/BamH1 sites. Subsequently, the CDS of human KIF5A was cloned from pWBC (Addgene clone #15239) and ligated in
frame with eGFP into the BAMH1/Xba1 sites. To make N-terminal HA-tagged KIF5AWT, KIF5ADExon27, and KIF5ADC-term, HA
sequence was added by inclusion into the forward primer for KIF5A variants by PCR and this sequence was ligated into the
Nhe1/BamH1 sites of pCDNA 3.1 (+). A flexible linker (GGSGx2) was added to all constructs by addition to the forward primer for
the KIF5A CDS. All constructs were sequenced and prepped with Invitrogen PureLink HiPure Plasmid Midiprep Kit. To generate
Myc- and Halo-tagged KIF5A constructs, a C-terminal Halo tag was first cloned by PCR and ligated into HindIII/AflII sites in the
pRK5:Myc-KIF5A vector (Addgene clone #127616). The KIF5AWT, KIF5ADExon27, and KIF5ADC-term, and KIF5AK560 sequences were
then subcloned into the pRK5 vector using EcoNI/AflII sites.
KIF5A survival experiments
On DIV5, immediately prior to transfection, all the conditioned neurobasal medium was removed, saved, and replaced with 25mL prewarmed OptiMEM serum-free media (Invitrogen 11058021). Transfected was done with 0.05% Lipofectamine 2000 (Invitrogen
11668019) and 28 ng DNA for 3.5 h at 37 C. A ratio of 7:1 was used for KIF5A and tdTomato vectors. After incubation, cells were
washed once with pre-warmed neurobasal medium and a 1:3 mix of conditioned to fresh complete medium was added. Cells
were imaged using the BioTek Cytation 5 multi-mode plate reader every 24 h. The plate was incubated at 37 C and 5% CO2 between
imaging runs with the BioTek BioSpa automated incubator. For the survival analysis, images were exported from the Cytostation 5
and aligned using Image J. Analysis was performed using custom python scripts and machine learning libraries from TensorFlow and
Keras. Two different convolutional neural networks (CNN) were trained to perform the survival analysis. Cortical neurons were detected at the first timepoint using the YOLOv2 algorithm which was trained to identify primary cortical neurons. The health of the identified cells was examined at all other timepoints using DenseNet201 which was trained to classify cells as alive or dead. The results
from the CNN analysis were exported to a CSV file and processed using R stats. All analysis was performed using Google
Collaboratory.
Immunofluorescence
For KIF5A localization in SKNAS cells were grown to 75% confluency then media was removed and replaced with fresh media. After
an 1 h incubation at 37 C, the cells were transfected with Lipofectamine 2000 (Invitrogen) using a DNA:Lipo ratio of 3 mg:8 ul per 6 well
according to the manufacturer’s instructions. Twenty-four hours after transfection, the cells were fixed in 4% PFA for 15 min at RT
then gently rinsed with 1X PBS. After removing the PBS, the coverslips were blocked in PBSAT (1X PBS+ 1% BSA+ 0.5% Triton
X-100) for at least 1hr. Subsequent antibody incubations on the coverslips were done for 1 h with the antibodies diluted in
PBSAT. Between antibody incubations, the coverslips were washed with PBSAT. After the final antibody incubation, the coverslips
were washed with PBSAT followed by 1X PBS. The coverslips were rinsed in water and mounted on slides using Prolong Gold + DAPI
(Invitrogen). All steps were carried out at room temperature. For V5-tagged KIF5A localization experiments, 1:1000 mouse anti-V5
(Invitrogen) and 1:200 rabbit anti-b-tubulin (Cell Signaling, 9F3) antibody was used. Nucleocytoplasmic staining used the following
antibodies: 1:200 rabbit anti-RBM24 (Thermo Fisher) and 1:200 rabbit anti-RAN (Bethyl Labs) antibody. IPS and I3 MN were stained
using the same method as the SKNAS cells with the following markers: 1:1000 mouse anti-Sox2 (R&D Systems), 1:1000 mouse antiOct4 (R&D Systems) and 1:500 mouse anti-Islet1/2 (Developmental Studies Hybridoma Bank). For I3 maturity marker staining, the
following primaries were incubated overnight at 4 C: 1:200 goat anti-ChAT (Millipore), and 1:2000 rabbit anti-MAP2. All other primary
antibodies were incubated with the cells for 1 h at RT. Host matched secondary antibodies (Jackson Immunoresearch) were diluted
1:1000 in PBSAT (1X PBS +1% BSA + 0.5% Triton X-100) and incubated for 1 h at room temperature. Cy5-conjugated Tuj1 (Biolegend) was applied to I3 neurons at 1:400 for 1 h at ambient temperature following secondary antibody incubations. Cells were
mounted in ProLong Gold anti-fade reagent with DAPI (Invitrogen).
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For KIF5A localization in N2A cells, they were plated at a density of 4.5 3 105 cells in 35 mm dishes 24 h before transfection using
Lipofectamine 3000 (Invitrogen) per manufacturer instructions. 2.5 micrograms of DNA was used for all experiments and for cotransfection of GFP-KIF5AWT along with HA-KIF5A variants a 1:1 ratio was used. At 24 h after transfection, the cells were trypsinized and
replated on Poly D-Lysine (Sigma) coated glass coverslips at a density of 1.5 3 105 cells in a 35 mm dish. The cells were grown in
standard growth media for 24 h and differentiation was performed by switching the media to differentiation media for an additional 48
h. Cells were fixed in 4% Formaldehyde diluted in 1X PBS for 10 min at RT. Cell were blocked using 1% BSA in 1X TBS with 0.1%
Triton X-100 for 1 h at RT. HA staining was performed using mouse monoclonal HA antibody CA 215 for 1 h at RT and anti-mouse
secondary antibodies for 1 h at RT: for expression alone FITC (Jackson) and for coexpression experiments TRITC (Jackson). Coverslips were mounted onto a glass slide using mounting media (Calbiochem Mowiol Reagent added to Glycerol and diluted in PBS).
For KIF5A localization staining in PMNs, DIV2 PMNs were transfected with HA-KIF5A plasmids and TdTomato plasmid using
1.75 mL NeuroMag reagent (OZ Biosciences) + 0.5 mg DNA. Complete growth medium was replaced with serum-free neurobasal medium 1 h prior and removed 1 h after transfection. At DIV6 cells were fixed with 4% PFA Fixed motor neurons were treated with hot 10
mM citrate buffer, pH 6 for 20 min before permeabilization with 0.25% Triton X-100 for 10 min. Cells were blocked with 5% BSA for
40 min and hybridized with the appropriate antibodies overnight at 4 C. Anti-mouse (Jackson, 488) and anti-rabbit (Jackson, 647)
secondary antibodies were hybridized for 1 h at room temperature. Coverslips were mounted onto a glass slide using Prolong Gold
mounting medium (Thermo Fisher).
Image analysis
KIF5A localization in SKNAS cells
Cells were imaged in stacks with a 0.3 mm step size using a Leica DMI6000 widefield microscope with a 63x lens. For KIF5A MT association and plus-end accumulation, the percentage of transfected cells (V5 positive) with these characteristics were counted in a
blinded fashion by two separate observers.
KIF5A localization in PMNs
Cells were imaged using a Nikon TiE widefield microscope with a cooled CMOS camera (Andor Zyla) using a 320 lens. Immunofluorescence images were deconvolved using an adaptative blind deconvolution algorithm (Autoquant X3, Media Cybernetics) before
analysis. To measure fluorescence intensities, the signals were thresholded and the resulting integrated densities were normalized on
the area of the selected region (e.g., growth cone, nucleus). The axon was identified as the longest neurite processing from the
neuron, with the growth cone determined by morphology at the axon terminal of the axon, using the TdTomato signal. Thresholds
were kept consistent for all images within experiments. For all experiments, values were normalized to HA-KIF5AWT.
KIF5A localization in N2A cells
Cells were imaged using a Nikon Eclipse Ti widefield microscope with an X-Cite LED1 light source and Photometrics Prism 95B camera. Images were taken the 40X lens at 1.5X magnification with stacks at a 0.3 mm step size. Exposure was kept consistent for all
images within experiments. Analysis was performed in blinded fashion. FIJI was used to generate maximum intensity projections
and plot profile analysis was performed as previously described (Lu et al., 2018, 2020). In brief, a segmented line (width 1) was drawn
from the edge of the cell nucleus to the tip of the longest neurite and the plot profile command was entered. The data output containing mean gray value along various distances along the line is saved. A MATLAB script was used to normalize the distance from
minimum 0 to maximum of 100 and intensity from minimum 0 to maximum 1 and is available upon request. Subanalysis was performed by stratifying the data 0–50 (soma and proximal neurite), 51–100 (distal neurite) followed by identifying the maximum normalized intensity in each of these 2 segments using the max function.
N:C ratio analysis
Cells were imaged using a 63x lens on a Leica DMI6000 widefield microscope. Cells were imaged in a stack with a 0.3 mm step size
through the entire cell. Sum projections of the stacks were created and a 20 3 20 pixel ROI was used to capture mean intensity
measurements. One ROI was placed in the center of the nucleus avoiding nucleoli (nuclear mean), one was placed in the cytoplasm
adjacent to the nucleus (cytoplasmic mean), and one was placed in a region of the field of view that lacked cells (for background subtraction). DAPI and Tuj1 staining was used to define the nuclear and cell body borders, respectively. The mean intensity of the background ROI was subtracted from the nuclear and cytoplasmic ROIs then a ratio of nuclear/cytoplasmic mean intensity was
calculated.
Transport assays
Single-molecule KIF5A assay
Cells were transiently transfected with Fugene 6 (Roche) according to the manufacturer’s instructions and harvested 20–24 h posttransfection. COS-7 cells expressing Halo-tagged KIF5A constructs were labeled with 2.5 mM TMR-Halo ligand (Promega) for 15 min
in the culture medium. Cells were then washed 2x with Ca2+- and Mg2+-free Dulbecco PBS (GIBCO), returned to the culture medium,
and left in the incubator for 30 min. The cells were then washed 2x with PBS, collected in PBS, and centrifuged at 5000 3 g for 5 min.
The resulting cell pellet was resuspended in a solution containing 40 mM HEPES, 1 mM EDTA, 120 mM NaCl, 0.1% Triton X-100,
1 mM DTT, and 1 mM magnesium ATP (pH 7.4) supplemented with protease inhibitors (1 mM PMSF, 0.001 mg/mL pepstatin A,
0.01 mg/mL leupeptin, and 0.01 mg/mL Na-p-tosyl-L-arginine methyl ester) and left on ice for 10 min. The lysate was then clarified
at 17,000 3 g at 4 C for 1 min.
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MT seeds were made by combining unlabeled tubulin with HiLyte488-labeled tubulin (Cytoskeleton) in BRB80 buffer (80 mM
PIPES, 1 mM EGTA, and 1 mM MgCl2 (pH 6.8)) at a 1:20 ratio of labeled to unlabeled tubulin and a final concentration of 50 mM.
This tubulin mixture was clarified at 352,000 3 g for 10 min at 4 C. The resulting supernatant was then incubated with 1 mM
GMPCPP at 37 C for 30 min to polymerize and stabilize MTs. A mixture of soluble tubulin was prepared by combining a 1:20 ratio
of unlabeled to HiLyte488-labeled tubulin as above. This tubulin mixture was clarified at 352,000 3 g for 10 min at 4 C and left on ice.
Flow chambers were constructed by attaching #1.5 glass coverslips (Warner) to glass slides (Fisher Scientific) with double-sided
tape. Coverslips were cleaned via sonication in acetone, potassium hydroxide, and ethanol, plasma cleaned and silanized with
PlusOne Repel-Silane (GE Healthcare) to reduce nonspecific binding. Flow chambers were first incubated with 0.5 mM rigor
kinesin-1 E236A for 5 min, then washed and blocked with 5% Pluronic F-127 (Sigma) for 5 min. After blocking, a 1:200 dilution of
GMPCPP-stabilized MTs was flowed into the chamber and allowed to incubate for 2 min. The chamber was then washed with
P12 buffer (12 mM PIPES, 1 mM EGTA, 2 mM MgCl2) to remove unbound MTs. A final solution containing 1 mM Mg-ATP, 1 mM
Mg-GTP, 10 mM soluble tubulin mixture, and 1:20 cell lysate in Dynamic Assay Buffer (P12, 0.3 mg/mL BSA, 0.3 mg/mL
casein, 10 mM DTT, 15 mg/mL glucose, 0.05% methylcellulose) and an oxygen scavenging system (0.5 mg/mL glucose oxidase,
470 U/mL catalase; Sigma) was flowed into the chamber. The chamber was then moved to 37 C and allowed to thermally equilibrate
for 5 min before video acquisition. For each chamber, three to five videos lasting 3 min were acquired at 37 C. The KIF5A channel
was acquired at 4 frames/second and the MT channel was acquired at 1 frame every 10 s. Imaging was performed on a Nikon Eclipse
Ti Inverted Microscope equipped with an Ultraview Vox spinning disk TIRF system and 100 3 1.49 NA oil immersion objective (Nikon).
Signals were collected using a Hamamatsu EMCCD C9100-13 camera, with a pixel size of 158 nm, controlled by Volocity software
(PerkinElmer). Kymograms of the KIF5A channel were generated by plotting a segmented line along each MT at its maximum length
using the Multi Kymograph macro in ImageJ. The plus-end of each MT was identified as the end with higher growth rates and catastrophe throughout the video. Kymograms were manually analyzed to determine the number of binding events and processive
runs. Non-motile binding was defined as any particle that associates with the MT for at least 1 s (4 frames) and has a displacement
of less than 4 pixels (632 nm). Processive motility was defined as any particle that associates with the MT for at least 1 s (4 frames) and
displays unidirectional movement for a minimum of 4 pixels (632 nm). Each processive segment was analyzed as a separate run for
particles that exhibited pauses of at least 1 s between processive movements.
Mitochondrial trafficking
Primary motor neurons (DIV2) were co-transfected using NeuroMag paramagnetic nanobeads (Oz Biosciences) with the dsRed-mito
reporter (Clontech) and different untagged KIF5A constructs in a 1:2 ratio. Briefly, complete neuronal medium was removed 1hr prior
to magnetofection and replaced with serum-free Neurobasal/B27 medium. 0.5mg plasmid DNA was added and incubated with 1.75 ml
NeuroMag beads in 100ml minimum essential medium (MEM) for 15 min, then added drop wise to cultures. Cell plates were then
placed on top of a magnetic plate (Oz Biosciences) for 15 min. After 1hr, complete Neurobasal medium was added back to cells.
Twenty-four hours after transfection, cells were imaged using a widefield fluorescence microscope (Nikon) equipped with a 20x
objective. Time lapses were acquired with a frame rate of 1 frame/second for a duration of 2 min. Analysis of mitochondria movement
was performed on a 100 mm proximal axonal fragment using the Image J plugin Mtrack J (Meijering et al., 2012).
Immunoprecipitations
For transfection of the IP constructs, SKNAS were handled as described under the immunofluorescence section. For co-transfections, the DNA amount was divided equally between the constructs. The constructs were allowed to express for 24 h before harvesting in DHL buffer (Singh et al., 2014) + protease inhibitors (Roche). The protein concentration of the lysates was determined by the
Pierce BCA Protein Assay kit (Thermo Fisher) per the manufacturer’s instructions. V5-antibody conjugated magnetic beads (MBL),
were washed 3x with 1X PBS+0.1% Tween 20 (PBS-T) before combining it with lysate in a 1mL:2 mg ratio (ex. 100ml of beads for
200 mg of lysate). The IP was incubated overnight at 4 C before collecting the flow-through (FT) and washing the beads 3x with
PBS-T. For immunoprecipitation confirmation proteins were eluted in 2X loading sample buffer (Boston Bio) by boiling. For mass
spec identification of KIF5A binding partners, the proteins were eluted by incubating the beads twice in 30ul of ‘‘soft elution buffer’’
(Antrobus and Borner, 2011) for 10 min at 28 C in a thermomixer set to 1000 rpm. Elution samples were sent to the UMASS Medical
School Mass Spectrometry facility for preparation and mudpit analysis. To identify the RNA binding partners, 0.2 U/mL SUPERase In
(Invitrogen) was added to DHL and PBS-T buffers before their use. During the final wash 10% of the bead/wash solution was set aside
for QC analysis with input and FT samples. RNAs were isolated from the IP beads by incubation in DHL buffer + SUPERase In + 0.1%
SDS + 0.3 mg/mL PCR grade Proteinase K (Fisher Scientific) for 30 min at 55 C in a thermomixer set to 300 rpm. The resulting supernatant was separated from the beads and the RNA extracted using Trizol reagent (ThernoFisher Scientific) according to the manufacturer’s instructions. The final RNA sample was resuspended in 5ul of nuclease-free water and sent to the Yale Genomic Core,
where 2 ng of each sample was used as input RNA for library construction and sequencing.
For the KIF5A interactions, V5- and HA-tagged KIF5A interactions were confirmed by immunoprecipitation as described above.
For interaction of GFP-tagged KIF5A with HA-tagged KIF5A, transfection of HEK293FT cells was performed by calcium phosphate
method. pCDNA 3.1 (+) GFP KIF5A WT was transfected either alone or in equal amounts with pCDNA 3.1 (+) HA-KIF5A WT, HA-KIF5A
DExon27, or HA-LIC. Pulldown by GFP binder was performed as described previously (Lu et al., 2018). Briefly, HEK293FT cells were
harvested 48 h post-transfection in 500ml of 10 mM Tris buffer, pH 7.4, containing 150 mM NaCL, 0.5 mM MgCl2 and protease inhibitor cocktail. After homogenization, 1% Triton X-100 was added to the solution and was centrifuged at 5,000xg at 4 C. Soluble
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fractions were incubated for 4 h at 4 C along with 30ml single-chain GFP antibody conjugated Sepharose beads (Gift from Vladimir
Gelfand Lab). Beads were washed in the same buffer as above, minus Triton X-100, and resuspended in 30–50mL Laemmli sample
buffer. Samples were boiled for 5 min and subsequently analyzed by Western blotting.
Mass spec analysis
Immunoprecipitated elution samples were analyzed by LC-MS/MS at UMASS Mass Spectrophotometry Facility. Raw data was processed using Thermo Proteome Discoverer 2.1.1.21 (Thermo Fisher Scientific Inc.) pipeline. The database search was performed by
Mascot Server 2.6.2 (Matrix Science Ltd) search engine using the following search parameters: Homo Sapiens Swiss-Prot database
FASTA file (download 04/2019); trypsin digestion with 2 maximum missed cleavages; the precursor mass tolerance of 10 ppm for the
monoisotopic mass, and the fragment mass tolerance of 0.05 Da; carbamidomethylation of cysteine specified as the fixed modification and peptide N-terminal acetylation, methionine oxidation, N-terminal glutamine to pyroglutamate conversion specified as a
variable modifications. Peptide and protein validation and annotation was done in Scaffold 4.10.0 (Proteome Software Inc.) employing Peptide Prophet (Keller et al., 2002) and Protein Prophet (Nesvizhskii et al., 2003) algorithms. Peptides were filtered at a 1% FDR,
while the protein identification threshold was set to greater than 99% probability and with a minimum of 2 identified peptides per
protein. Normalized iBAQ (Schwanhäusser et al., 2011) values were assigned to identified proteins for the quantitative comparison.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol
et al., 2022) partner repository with the dataset identifier PXD031012 and 10.6019/PXD031012. Pathway analysis was completed
using Metascape (Zhou et al., 2019).
Differential gene expression and alternate splicing RNAseq analysis
RNA samples were extracted and sequenced on an Illumina HiSeq2000 instrument at the Yale Center for Genome Analysis. The sample sequences were checked for overall quality and possible adapter contamination using FastQC (available at https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/) and MultiQC (Ewels et al., 2016) tools. The read length was 101 and 151 for
KIF5A RNA-Seq and RIP-Seq data, respectively. FASTQ files were mapped to the GRCh38 genome using STAR aligner (2.7.0a) (Dobin et al., 2013) in two-pass mode with the splice aware option. In particular, -outSAMtype BAM SortedByCoordinate was used to
produce sorted bam and –sdjbOverhang 100 for optimal splice junction overhang length. Read counts were computed for each transcript based on gencode version 33 annotation using HTSeq (Anders et al., 2015) tool in strand-specific mode. After generating
HTSeq counts, Differential expression analysis was performed using the DESeq2 package to compare the gene expression profiles
(Love et al., 2014). Further in the downstream analysis process, the transcripts with a sum of R20 reads in all samples were selected
for further analysis to remove the transcript with low count reads from the study. To further process the RIP experiment, genes with
R20 read counts were compared between experiments. Only those genes found overlapping between the experiments (in either or
both of the samples) were further analyzed. The differential expression experiment between wild-type and mutant was performed
using the Wald test to generate p values and Log2 fold changes. The STAR aligned RNA Sequence sample bam files were used
to detect differential alternative splicing events with the Multivariate Analysis of Transcript Splicing (MATS) method (using rMATS
version 4.0.2) with a threshold of FDR<0.05 and splicing difference >0.1. rMATS uses a hierarchical framework to model exon inclusion levels to detect differential splicing events (Shen et al., 2014). Pathway analysis was completed using Metascape (Zhou et al.,
2019). Analysis of RNA-binding proteins binding sites with positional dependent functions was performed using rMAPS2 (Hwang
et al., 2020) directly on the rMAPS2 webserver located at http://rmaps.cecsresearch.org/.
qPCR analysis
Total RNA was isolated from DIV15 iMNs using the Qiagen RNAeasy Mini KIT (74104). Using the High Capacity cDNA reverse
transcription kit (Applied Biosystems, 436814), RNA was reverse transcribed. Quantitative real-time PCR was performed in the
Bio Rad CFX384 Real Time System with C1000 Touch Thermal Cycler using the TaqMan Fast Advanced Master Mix
(ThermoFisher, 4444556) and TaqMan Gene Expression Assay KITS (FAM, Hs01028461_s1, Hs04194669_sH, Hs00259032_s1,
Hs01115690_m1, Hs00388055_m1, Hs00956610_mH, Hs02786624_g1). For relative expression, DDCq method was employed,
using GAPDH as an internal control. For each differentiation, quantitative RT-PCR was measured in triplicate and the mean for
each differentiation used for analysis. A two-way ANOVA followed by Sidak’s multiple comparison test was performed to determine significance.
Western blotting
Western blot analyses were performed by running protein lysates 10% polyacrylamide gels or gradient gels Bio-Rad) as needed.
Transfers onto nitrocellulose membranes (Bio-rad) were completed using a Trans-blot Turbo (BioRad) apparatus according to the
manufactuer’s instructions. Membranes were blocked in a 1:1 solution of blocking buffer (Licor) and 1X PBS-T (IX PBS+ 0.01%
Tween) for at least 1hr on a rocker at room temperature. Primary antibodies were diluted in PBS-T and incubated with the membrane
overnight at 4 C. After washing the membrane in PBS-T on the rocker at room temperature 3x for 5 min each, secondary antibodies
were diluted in a 1:1 solution of blocking buffer + PBS-T and incubated with the membrane on a rocker for at least 1hr. The membrane
was washed as before and imaged on the Odyssey Imager (Licor) according to the manufacturer’s instructions. Primary antibodies
were used as follows: 1:5,000 for mouse anti-V5 (Invitrogen), 1:1000 rabbit anti-V5 (Novus), and 1:1000 rabbit anti-HA (Sigma). Mouse
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anti-Hemagglutinin (HA) antibody (Invitrogen) and Rabbit anti-GFP antibody (Proteintech) were both used to probe GFP-pulldown
lysate at 1:1000 dilution.
Blots were visualized with an Odyssey Infrared Imager (LiCor, Model 9120). Capillary Western blot analyses were done using the
WES system (Protein Simple) following the manufacturer’s instructions. Protein samples were mixed with 5x FL mastermix, boiled,
and loaded into the plate. Primary antibodies were used as follows: 1:5000 for mouse anti-V5 (Invitrogen), 1:1000 for mouse anti-Myc
(Sigma), 1:60 for rabbit anti-panKIF5A (Genetex), 1:60 for rabbit anti-mutKIF5A (Genewiz). and 1:1500 for rabbit anti-GAPDH (Novus
Biologicals).
For immunoblotting of GFP-binder pulldown equal amounts of lysate were diluted in Laemli buffer and loaded into handcast trisglycine-SDS gels. Separation was performed using the Idea Scientific Minislab. Wet transfers to nitrocellulose membrane was performed using classic wet tank transfer for 1hr (Biorad). All blocking and antibody incubations were performed using 5% nonfat milk
diluted in TBST. The membrane was blocked for 1 h at RT. Primary antibodies, 1:7000 rabbit anti-GFP (Proteintech) and 1:1000
mouse anti-HA CA-215 were incubated overnight at 4 C. Secondary antibody 1:5000 goat anti mouse HRP (Jackson) or 1:5000
goat anti rabbit HRP were incubated for 1hr. Chemiluminescent detection was performed using Anvansta WesternBright quantum
reagent and Licor Odyssey XF Imager.
Structure modeling
I-TASSER was utilized to predict the structure of KIF5AWT and KIF5ADExon27 and the strongest match was selected (Roy et al., 2010;
Yang et al., 2015; Zhang, 2008). All models were generated using PyMOL (Version 2.0, Schrodinger, LLC).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism (GraphPad v9, SanDiego, CA, USA) software. Samples were compared
by Students t-test unless otherwise specified in the figure legends. The number of replicates and p values are described in the legends. For reference, * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.

Cell Reports 39, 110598, April 5, 2022 e12

